Chemokines and chemokine receptors as therapeutic targets in lupus nephritis

被引：44

作者：

Vielhauer, Volker ^{[1
]}

Anders, Hans-Joachim ^{[1
]}

Schloendorff, Detlef ^{[1
]}

机构：

[1] Klinikum Univ Munchen, Med Poliklin Innenstadt, Munich, Germany

来源：

SEMINARS IN NEPHROLOGY | 2007年 / 27卷 / 01期

关键词：

chemokine; chemokine receptors; systemic lupus erythematosus; MRL/lpr mouse; leukocyte recruitment; kidney; receptor antagonist; polymorphisms;

D O I：

10.1016/j.semnephrol.2006.09.010

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Recruitment of leukocytes is a characteristic feature of tissue injury in systemic lupus erythematosus, including lupus nephritis. Locally secreted chemokines and their receptors are important mediators of leukocyte recruitment to the specific sites of immune complex injury, and contribute to renal inflammatory disease in the initiation and progression phase. Therefore, chemokines and chemokine receptors represent potential therapeutic targets in lupus nephritis. In this review we summarize available experimental and human data supporting their functional role in lupus nephritis. Moreover, interventional studies with chemokine and chemokine receptor antagonists that show the therapeutic potential of chemokine antagonists in experimental models of lupus nephritis and potentially in human renal disease are discussed. © 2007 Elsevier Inc. All rights reserved.

引用

页码：81 / 97

页数：17

共 103 条

[1]

Aguilar F, 2003, J RHEUMATOL, V30, P1770

[2] MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus [J].

Aguilar, F ;

González-Escribano, MF ;

Sánchez-Román, J ;

Núñez-Roldán, A .

TISSUE ANTIGENS, 2001, 58 (05) :335-338

[3] Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice [J].

Anders, HJ ;

Belemezova, E ;

Eis, V ;

Segerer, S ;

Vielhauer, V ;

De Lema, GP ;

Kretzler, M ;

Cohen, CD ;

Frink, M ;

Horuk, R ;

Hudkins, KL ;

Alpers, CE ;

Mampaso, F ;

Schlöndorff, D .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06) :1504-1513

[4] Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice [J].

Anders, HJ ;

Vielhauer, V ;

Eis, V ;

Linde, Y ;

Kretzler, M ;

de Lema, GP ;

Strutz, F ;

Bauer, S ;

Rutz, M ;

Wagner, H ;

Gröne, HJ ;

Schlbndorff, D .

FASEB JOURNAL, 2004, 18 (01) :534-+

[5] CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration [J].

Anders, HJ ;

Frink, M ;

Linde, Y ;

Banas, B ;

Wörnle, M ;

Cohen, CD ;

Vielhauer, V ;

Nelson, PJ ;

Gröne, HJ ;

Schlöndorff, D .

JOURNAL OF IMMUNOLOGY, 2003, 170 (11) :5658-5666

[6] Chemokines and chemokine receptors are involved in the resolution or progression of renal disease [J].

Anders, HJ ;

Vielhauer, V ;

Schlöndorff, D .

KIDNEY INTERNATIONAL, 2003, 63 (02) :401-415

[7] Bacterial CpG-DNA aggravates immune complex glomerulonephritis:: Role of TLR9-mediated expression of chemokines and chemokine receptors [J].

Anders, HJ ;

Banas, B ;

Linde, Y ;

Weller, L ;

Cohen, CD ;

Kretzler, M ;

Martin, S ;

Vielhauer, V ;

Schlöndorff, D ;

Gröne, HJ .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (02) :317-326

[8]

Anders HJ, 2001, J AM SOC NEPHROL, V12, P919, DOI 10.1681/ASN.V125919

[9] Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention [J].

Aringer, M ;

Smolen, J .

LUPUS, 2004, 13 (05) :344-347

[10] Measurement of urinary chemokine and growth factor messenger RNAs: A noninvasive monitoring in lupus nephritis [J].

Avihingsanon, Y ;

Phumesin, P ;

Benjachat, T ;

Akkasilpa, S ;

Kittikowit, V ;

Praditpornsilpa, K ;

Wongpiyabavorn, J ;

Eiam-Ong, S ;

Hemachudha, T ;

Tungsanga, K ;

Hirankarn, N .

KIDNEY INTERNATIONAL, 2006, 69 (04) :747-753

← 1 2 3 4 5 6 7 8 9 10 →